Key terms
About BPMC
Blueprint Medicines Corp. is a precision therapy company, which engages in the invention of medicines for people with cancer and blood disorders. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest BPMC news
Apr 09
4:25pm ET
Blueprint Medicines Buy Rating: Promising BLU-222 Efficacy and Strong Financial Outlook
Apr 05
6:40am ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: Bausch Health Companies (BHC), Blueprint Medicines (BPMC) and Evolent Health (EVH)
Feb 26
6:37am ET
Cogent Biosciences price target raised to $13 from $11 at Citi
Feb 26
6:20am ET
Analysts Offer Insights on Healthcare Companies: Blueprint Medicines (BPMC), Legend Biotech (LEGN) and Celldex (CLDX)
Feb 26
6:15am ET
Blueprint Medicines Receives Sell Rating Amidst Modest Polypharmacy Reduction and Negative Share Price Projections
Feb 26
5:55am ET
Buy Rating Affirmed for Blueprint Medicines on Strong Ayvakit Clinical Performance and Promising Pipeline
Feb 26
12:30am ET
Analysts Offer Insights on Healthcare Companies: Blueprint Medicines (BPMC), AMN Healthcare Services (AMN) and Ironwood Pharma (IRWD)
Feb 25
11:30pm ET
Blueprint Medicines: Sell Rating Justified by Gavreto Divestiture and Strategic Shift
Feb 23
8:08am ET
Blueprint Medicines announces PIONEER trial results
Feb 23
7:21am ET
Stifel Nicolaus Keeps Their Buy Rating on Blueprint Medicines (BPMC)
Feb 23
3:15am ET
Barclays Sticks to Its Hold Rating for Blueprint Medicines (BPMC)
Feb 22
8:33am ET
Blueprint Medicines Divests GAVRETO Rights to Rigel
Feb 18
11:45pm ET
Blueprint Medicines Sell Rating: Assessing Ayvakit’s Market Potential and Financial Concerns
Feb 16
9:29am ET
Blueprint Medicines price target raised to $97 from $92 at Needham
Feb 16
7:49am ET
Blueprint Medicines price target lowered to $107 from $115 at Wells Fargo
Feb 16
7:19am ET
Sell Rating on Blueprint Medicines Amidst Concerns Over Long-Term Growth and Financial Outlook
Feb 16
7:01am ET
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Blueprint Medicines (BPMC) and Medtronic (MDT)
Feb 16
6:54am ET
Blueprint Medicines price target raised to $65 from $54 at Citi
Feb 16
6:09am ET
Blueprint Medicines price target raised to $125 from $85 at H.C. Wainwright
Feb 16
5:17am ET
Blueprint Medicines: Strong Buy on Impressive Q4 Earnings and Promising Ayvakit Revenue Projections
Feb 16
1:41am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Feb 15
3:35pm ET
Blueprint Medicines: A Strong Buy on Surging Ayvakit Sales and Promising Market Expansion
Feb 15
3:07pm ET
Blueprint Medicines price target raised to $99 from $90 at Oppenheimer
Feb 15
2:20pm ET
Analysts Are Bullish on These Healthcare Stocks: Blueprint Medicines (BPMC), Citius Pharmaceuticals (CTXR)
Feb 15
8:05am ET
Blueprint Medicines Receives Buy Rating Amid Surpassing Sales and Optimistic Financial Outlook
Feb 15
7:10am ET
Blueprint Medicines provides 2024 financial guidance
Feb 13
5:42am ET
Blueprint Medicines (BPMC) Receives a Hold from Barclays
Feb 05
8:20am ET
Analysts Are Bullish on Top Healthcare Stocks: Regeneron (REGN), Arcellx Inc (ACLX)
Jan 30
10:17pm ET
Blueprint Medicines price target raised to $90 from $85 at Oppenheimer
Jan 22
2:42pm ET
Buy Rating Affirmed for Blueprint Medicines with Strong Outlook on Ayvakit’s Market Growth and Financial Performance
Jan 22
2:40pm ET
Analysts Offer Insights on Healthcare Companies: SurModics (SRDX), Urogen Pharma (URGN) and Blueprint Medicines (BPMC)
No recent press releases are available for BPMC
BPMC Financials
Key terms
Ad Feedback
BPMC Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
BPMC Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
